ClinicalTrials.gg
TerminatedNCT05723107Updated Nov 6, 2026

EUS RFA for Treatment of Pancreatic Ductal Adenocarcinoma (PDAC)

A Phase 1 interventional study of Chemotherapy and Endoscopic Ultrasound-Guided Radiofrequency Ablation (EUS-RFA) in Pancreatic Cancer, sponsored by NYU Langone Health. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by NYU Langone Health · Phase 1, Interventional, and Treatment

How we know

Why this study was terminated
Halted prematurely

From the registry’s dates

  • Primary completion was Nov 2024, 1 year 11 months ago, and no results have been posted to the registry.
Updated Nov 6, 2026Now TerminatedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Pancreatic Neoplasms by NYU Langone Health — none open to participants now, 1 under way, none of them phase 3. Pancreatic Neoplasms · NYU Langone Health.

Enrollment
8th of 10
6 · median 13
Started
2023
with 1 other
Phase 1
5 of 12
none open now
Registered
11th of 12
by date

Among the 12 studies in Pancreatic Neoplasms by NYU Langone Health, this one is the 8th largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2023, is one of 5 in phase 1, and was the 11th registered.

Pancreatic Neoplasms

3,903 studies on the registry are indexed under Pancreatic Neoplasms; 1,005 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

None of the 12 studies in Pancreatic Neoplasms by NYU Langone Health is open now. The open studies under Pancreatic Neoplasms, anywhere →

Where they have run

Who these studies take

Of the 743 Pancreatic Neoplasms studies recruiting now, 476 (64%) set no upper age limit and 153 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies in Pancreatic Neoplasms by NYU Langone Health as a file.
02

Study summary

This is a single arm study in the treatment of pancreatic ductal adenocarcinoma (PDAC). The investigators propose to test the tolerability of chemotherapy plus endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) using the RF Electrode in patients receiving palliative second or third line therapy for unresectable non-metastatic pancreatic cancer.

03

Conditions studied

  • Pancreatic Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed and confirmed PDAC by
  • Axial CT scan or MRI consistent with PDAC with at least 1 cm in greatest diameter
  • performance status 0-2
  • Patients with locally advanced PDAC, who have not responded or progressed on chemotherapy, are deemed not resectable based on multidisciplinary review, and show no evidence of distant
  • Lesions between 1 - 4cm in size

Exclusion criteria

Exclusion Criteria:

  • Patients that show evidence of distant
  • Endoscopically non-accessible mass
  • Pregnant patients
  • Inability to provide
  • Lesions \<1cm, or >4cm in greatest diameter
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    Chemotherapy plus EUS-RFA

    Endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) and chemotherapy will be administered as part of standard of care treatment for PDAC in patients receiving palliative second- or third-line therapy for unresectable non-metastatic pancreatic cancer. Study participants will undergo 3 identical EUS-RFA procedures, administered during Study Window 2 (Weeks 1-3), Window 3 (Weeks 5-7), and Window 4 (Weeks 9-11). During each EUS-RFA procedure, a tumor biopsy will also be taken for single cell RNA sequencing. Chemotherapy will be administered during Study Window 2 (Weeks 1-3), Window 3 (Weeks 5-7), Window 4 (Weeks 9-11), and Window 5 (Weeks 13-15).

    Drug: Chemotherapy · Device: Endoscopic Ultrasound-Guided Radiofrequency Ablation (EUS-RFA)

Interventions

  • DrugChemotherapy

    Patients will receive continuation of second or initiate third-line chemotherapy regimen at the discretion and decision of treating oncologist.

  • DeviceEndoscopic Ultrasound-Guided Radiofrequency Ablation (EUS-RFA)

    EUS-RFA will be delivered using the EUSRA RF Electrode, which is a sterile, single-use electrosurgical accessory for coagulation and ablation of soft tissue when used in conjunction with compatible radio frequency generator (VIVA Combo RF Generator). The device will be used during a routine EUS, which is a minimally invasive procedure used to assess gastrointestinal diseases. Each EUS-RFA procedure will last approximately 60 minutes.

    Also known as: EUSRA RF Electrode

06

What researchers measure

Primary outcomes

  1. Percentage of Participants who Complete Therapy without Grade III-IV Adverse Events (AEs) as Assessed by CTCAE v. 5.0

    Per Common Terminology Criteria for Adverse Events (CTCAE) v. 5.0, Grade III AEs are defined as severe or medically significant but not immediately life-threatening; or hospitalization or prolongation of hospitalization indicated; or disabling; or limiting self care activities of daily living. Grade IV AEs are defined as life-threatening consequences; or urgent intervention indicated.

    Time frame: Up to Week 15

Secondary outcomes

  1. Percentage of Participants who Complete all 3 EUS-RFA Treatments

    Treatments delivered during Study Window 2 (Weeks 1-3), Window 3 (Weeks 5-7), and Window 4 (Weeks 9-11).

    Time frame: Up to Week 11

  2. Disease-Free Survival from Diagnosis

    Time from diagnosis to first clinical evidence of local or distant recurrence.

    Time frame: Up to Week 24

  3. Disease-Free Survival from First Study Procedure

    Time from first study procedure (delivered during Weeks 1-3) to first clinical evidence of local or distant recurrence.

    Time frame: Up to Week 24

  4. Overall Survival From Diagnosis

    Time from diagnosis to death.

    Time frame: Up to Week 24

  5. Percentage of Participants who Report Post-Procedural Complications

    Time frame: Up to Week 24

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — The de-identified participant data from the final research dataset used in the published manuscript will be shared upon reasonable request beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research provided the investigator who proposes to use the data executes a data use agreement with NYU Langone Health. Requests may be directed to: [Tamas.Gonda@nyulangone.org]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.

Access criteria: The investigator who proposed to use the data will be granted access upon reasonable request. Requests should be directed to Tamas.Gonda@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Mar 2023 to primary completion in Nov 2024, 19 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: primary completion Nov 2027 → Nov 2024 and completion Mar 2028 → Feb 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 1, 2023
First posted
Feb 10, 2023
StartActual
Mar 31, 2023
Primary completionActual
Nov 25, 2024was Nov 2027
CompletionActual
Feb 25, 2025was Mar 2028
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Terminated Halted prematurely
changed Nov 6, 2026
Primary completion
Nov 2027→Nov 25, 2024 (actual)
Nov 6, 2026
Study completion
Mar 2028→Feb 25, 2025 (actual)
Nov 6, 2026
Enrollment
15 (estimated)→6 (actual)
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Recruiting→Terminated
    Why stopped Halted prematurely
    Primary completion Nov 2027→Nov 25, 2024 (now actual)
    Study completion Mar 2028→Feb 25, 2025 (now actual)
    Enrollment 15 (estimated)→6 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05723107
Lead sponsor
NYU Langone Health
Collaborators
Taewoong Medical
Responsible party
Sponsor
First posted
Feb 10, 2023
Start date
Mar 31, 2023
Primary completion
Nov 25, 2024
Completion
Feb 25, 2025
Last update
Nov 6, 2026

Study contacts

Tamas A. Gonda, MD
principal investigator · NYU Langone Health

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion